(-)-Epigallocatechin Gallate Inhibits Stemness and Tumourigenicity Stimulated by AXL Receptor Tyrosine Kinase in Human Lung Cancer Cells

Overview

Journal Sci Rep

Specialty Science

Date 2020 Feb 14

PMID 32051483

Citations 18

Authors

Kozue Namiki

Pattama Wongsirisin

Shota Yokoyama

Motoi Sato

Anchalee Rawangkan

Ryo Sakai

Keisuke Iida

Masami Suganuma

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (H1299-sdCSCs) were obtained from tumour spheres of H1299 human lung cancer cells. We studied low stiffness, a unique biophysical property of cancer cells, in H1299-sdCSCs and parental H1299. Atomic force microscopy revealed an average Young's modulus value of 1.52 kPa for H1299-sdCSCs, which showed low stiffness compared with that of H1299 cells, with a Young's modulus value of 2.24 kPa. (-)-Epigallocatechin gallate (EGCG) reversed the average Young's modulus value of H1299-sdCSCs to that of H1299 cells. EGCG treatment inhibited tumour sphere formation and ALDH1A1 and SNAI2 (Slug) expression. AXL receptor tyrosine kinase is highly expressed in H1299-sdCSCs and AXL knockdown with siAXLs significantly reduced tumour sphere formation and ALDH1A1 and SNAI2 (Slug) expression. An AXL-high population of H1299-sdCSCs was similarly reduced by treatment with EGCG and siAXLs. Transplantation of an AXL-high clone isolated from H1299 cells into SCID/Beige mice induced faster development of bigger tumour than bulk H1299 cells, whereas transplantation of the AXL-low clone yielded no tumours. Oral administration of EGCG and green tea extract (GTE) inhibited tumour growth in mice and reduced p-AXL, ALDH1A1, and SLUG in tumours. Thus, EGCG inhibits the stemness and tumourigenicity of human lung cancer cells by inhibiting AXL.

Citing Articles

Medicinal plants as a potential resource for the discovery of novel structures towards cancer drug resistance treatment.

Nguyen M, Nguyen T, Le T, Le T, Chau N, Le T Heliyon. 2024; 10(20):e39229.

PMID: 39492898 PMC: 11530815. DOI: 10.1016/j.heliyon.2024.e39229.

The transcription factors NR5A1 and JUNB cooperate to activate the Axl promoter in mouse Sertoli cell lines.

Diawara M, Martin L Mol Biol Rep. 2024; 51(1):982.

PMID: 39271559 DOI: 10.1007/s11033-024-09934-3.

The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review.

Chaudhuri R, Samanta A, Saha P, Ghosh S, Sinha D Curr Med Chem. 2024; 31(32):5255-5280.

PMID: 38243984 DOI: 10.2174/0109298673281666231227053726.

Editorial: Plant-based drugs: the potential novel therapeutic intervention against cancer stemness and metastasis.

Liju V, Martin S, Nath L, Nair G, Thayele Purayil H Front Pharmacol. 2023; 14:1283694.

PMID: 37869751 PMC: 10588462. DOI: 10.3389/fphar.2023.1283694.

Characterization of stemness features and construction of a stemness subtype classifier to predict survival and treatment responses in lung squamous cell carcinoma.

Lai J, Lin X, Zheng H, Xie B, Fu D BMC Cancer. 2023; 23(1):525.

PMID: 37291533 PMC: 10251713. DOI: 10.1186/s12885-023-10918-y.

References

Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H . Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev. 2008; 17(11):3020-5. DOI: 10.1158/1055-9965.EPI-08-0528. View

Shin C, Lee D, Seo A, Lee H, Kim S, Son W . Green tea extracts for the prevention of metachronous colorectal polyps among patients who underwent endoscopic removal of colorectal adenomas: A randomized clinical trial. Clin Nutr. 2017; 37(2):452-458. DOI: 10.1016/j.clnu.2017.01.014. View

Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A . Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006; 66(2):1234-40. DOI: 10.1158/0008-5472.CAN-05-1145. View

Fujiki H, Imai K, Nakachi K, Shimizu M, Moriwaki H, Suganuma M . Challenging the effectiveness of green tea in primary and tertiary cancer prevention. J Cancer Res Clin Oncol. 2012; 138(8):1259-70. DOI: 10.1007/s00432-012-1250-y. View

Suganuma M, Saha A, Fujiki H . New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci. 2011; 102(2):317-23. DOI: 10.1111/j.1349-7006.2010.01805.x. View

Fujiki H, Sueoka E, Watanabe T, Suganuma M . Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds. J Cancer Res Clin Oncol. 2014; 141(9):1511-22. DOI: 10.1007/s00432-014-1899-5. View

Fujiki H, Sueoka E, Rawangkan A, Suganuma M . Human cancer stem cells are a target for cancer prevention using (-)-epigallocatechin gallate. J Cancer Res Clin Oncol. 2017; 143(12):2401-2412. PMC: 5693978. DOI: 10.1007/s00432-017-2515-2. View

Cross S, Jin Y, Rao J, Gimzewski J . Nanomechanical analysis of cells from cancer patients. Nat Nanotechnol. 2008; 2(12):780-3. DOI: 10.1038/nnano.2007.388. View

Takahashi A, Watanabe T, Mondal A, Suzuki K, Kurusu-Kanno M, Li Z . Mechanism-based inhibition of cancer metastasis with (-)-epigallocatechin gallate. Biochem Biophys Res Commun. 2013; 443(1):1-6. DOI: 10.1016/j.bbrc.2013.10.094. View

10.

Iida K, Sakai R, Yokoyama S, Kobayashi N, Togo S, Yoshikawa H . Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL. Sci Rep. 2017; 7(1):17770. PMC: 5736582. DOI: 10.1038/s41598-017-18120-4. View

11.

Liu E, Hjelle B, Bishop J . Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 1988; 85(6):1952-6. PMC: 279899. DOI: 10.1073/pnas.85.6.1952. View

12.

OBryan J, Frye R, Cogswell P, Neubauer A, Kitch B, Prokop C . axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991; 11(10):5016-31. PMC: 361494. DOI: 10.1128/mcb.11.10.5016-5031.1991. View

13.

Graham D, DeRyckere D, Davies K, Earp H . The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2015; 14(12):769-85. DOI: 10.1038/nrc3847. View

14.

Seike M, Kim C, Zou F, Noro R, Chiba M, Ishikawa A . AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier. Oncol Rep. 2017; 37(6):3261-3269. DOI: 10.3892/or.2017.5594. View

15.

Zhang Z, Lee J, Lin L, Olivas V, Au V, LaFramboise T . Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012; 44(8):852-60. PMC: 3408577. DOI: 10.1038/ng.2330. View

16.

Gay C, Balaji K, Byers L . Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer. 2017; 116(4):415-423. PMC: 5318970. DOI: 10.1038/bjc.2016.428. View

17.

Asiedu M, Beauchamp-Perez F, Ingle J, Behrens M, Radisky D, Knutson K . AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2013; 33(10):1316-24. PMC: 3994701. DOI: 10.1038/onc.2013.57. View

18.

Jin Y, Nie D, Li J, Du X, Lu Y, Li Y . Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin. Clin Cancer Res. 2016; 23(11):2842-2855. DOI: 10.1158/1078-0432.CCR-16-1298. View

19.

Watanabe T, Kuramochi H, Takahashi A, Imai K, Katsuta N, Nakayama T . Higher cell stiffness indicating lower metastatic potential in B16 melanoma cell variants and in (-)-epigallocatechin gallate-treated cells. J Cancer Res Clin Oncol. 2012; 138(5):859-66. DOI: 10.1007/s00432-012-1159-5. View

20.

Ali Haghparast S, Kihara T, Miyake J . Distinct mechanical behavior of HEK293 cells in adherent and suspended states. PeerJ. 2015; 3:e1131. PMC: 4525692. DOI: 10.7717/peerj.1131. View